Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Dose-escalating, P-C, D-B, Parallel Group Study in HIV Treatment-experienced Patients to Evaluate the Safety, Tolerability and Efficacy of PA103001-04 Administered as Functional Monotherapy for 14 Days *(PART B)

NCT00511368 is registered in ClinicalTrials.gov with Myrexis Inc. as lead sponsor.

NCT NCT00511368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00511368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Dose-escalating, P-C, D-B, Parallel Group Study in HIV Treatment-experienced Patients to Evaluate the Safety, Tolerability and Efficacy of PA103001-04 Administered as Functional Monotherapy for 14 Days *(PART B)
Lead sponsor
Myrexis Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2006
Completion date
July 31, 2008
Enrollment
92 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections